Plavix news from FierceBiotech
News
BMS inks $227M collaboration deal with KAI
South San Francisco-based KAI Pharmaceuticals is getting a $25 million boost from Bristol-Myers Squibb---its upfront payment for a collaboration on KAI-9803, an experimental therapy to reduce the Read more...
ALSO NOTED: AMA joins DTC advertising fray; U.K. toughening up on pharma promos; and much more...
> We all expected Democrats to rake DTC ads over the coals during yesterday's hearing before the House Energy and Commerce Committee's oversight arm. What we didn't expect was for the American Read more...
Lilly's prasrugel stands out in comparison study
Here's one other reason for Lilly to be upbeat today. In a head-to-head study, the new antiplatelet drug prasugrel (being developed by Lilly and Daiichi Sankyo) in combination with aspirin Read more...
Prasugrel gets priority review
The FDA has granted priority review to Eli Lilly and Daiichi Sankyo's prasugrel, an anti-clotting drug. The NDA for prasugrel was submitted to the agency in December. Now the drugmakers can expect an Read more...
Lilly submits prasugrel NDA
Eli Lilly and Daiichi Sankyo have submitted the much-watched drug prasugrel to the FDA. The drug--an oral antiplatelet agent--is poised to take on the blockbuster Plavix. Read more...
BMS sources discount chance of Sanofi buyout
Dow Jones is quoting sources close to Bristol-Myers Squibb who say that a buyout by Sanofi-Aventis is not in the Read more...
Investors fret over Lilly's pipeline, Prasugel data
Barron's concludes that Eli Lilly's anti-clotting drug Prasrugel will probably make it to the market, but recent safety data is likely to prevent it from becoming the kind of blockbuster the drug Read more...
Doubters see big obstacles for Lilly's Prasrugel
The news that Eli Lilly's experimental anti-clotting drug Prasrugel was linked with a higher risk of fatal bleeding has converted a large group of analysts into disbelievers in the company's stock Read more...
Lilly drug outperforms Plavix, but there's a catch
Eli Lilly's shot at a blockbuster heart drug was in question this morning after researchers unveiled new data showing that prasugrel outperformed a top competitor in the anti-clotting market while Read more...
Lilly suspends dosing in crucial drug trial
Eli Lilly and its partner Daiichi Sankyo moved swiftly to try and contain any damage from the news that Read more...
Get more Plavix coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets